Literature DB >> 22401837

Medical and developmental risk factors of catatonia in children and adolescents: a prospective case-control study.

Angèle Consoli1, Marie Raffin, Claudine Laurent, Nicolas Bodeau, Dominique Campion, Zahir Amoura, Frederic Sedel, Isabelle An-Gourfinkel, Olivier Bonnot, David Cohen.   

Abstract

CONTEXT: Rare diseases have been associated with more and more genetic and non genetic causes and risk factors. But this has not been systematically assessed in catatonia, one of the psychiatric syndromes, that is most frequently associated with medical condition.
OBJECTIVE: We sought to assess the medical and developmental risk factors of catatonia in children and adolescents.
METHODS: From 1993 to 2009, 58 youths aged 10 to 18 years were prospectively admitted for catatonia and were followed up after discharge. A multidisciplinary approach assessed patients' medical condition and developmental history. A causality assessment scored medical risk (maximum score=10; κ=0.91). We compared the prevalence of catatonia in these patients to that of 80 inpatients with bipolar I disorder admitted from 1993 to 2003 who were also followed up.
RESULTS: We found that 13 (22.4%) patients had medical conditions and 18 (31%) had a history of developmental disorder in the catatonia group, whereas 1 (1.3%) and 17 (22.6%) patients had the same conditions in the bipolar group (p<0.001; p=0.17, respectively). Medical conditions associated with catatonia included auto-immune encephalitis (systemic lupus erythematosus [N=3] and anti-NMDA-receptor encephalitis [N=1]), seizures (N=1), ciclosporin encephalitis (N=1), post hypoglycaemic coma encephalitis (N=1), and genetic or metabolic conditions (chorea [N=2], 5HT cerebrospinal fluid deficit [N=1], storage disease [N=1], fatal familial insomnia [FFI; N=1], and PRODH mutations [N=1]). Six patients responded to a specific treatment approach related to their medical condition (e.g., plasma exchange in the case of auto-immune encephalitis).
CONCLUSION: Catatonia in children and adolescents is associated with a high prevalence of medical conditions. This needs to be acknowledged as it may greatly delay the treatment of catatonia and the diagnosis of medically related catatonia. Tragically, this may deny patients treatment opportunities.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22401837     DOI: 10.1016/j.schres.2012.02.012

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  16 in total

1.  Treatment use in a prospective naturalistic cohort of children and adolescents with catatonia.

Authors:  Marie Raffin; Laetitia Zugaj-Bensaou; Nicolas Bodeau; Vanessa Milhiet; Claudine Laurent; David Cohen; Angèle Consoli
Journal:  Eur Child Adolesc Psychiatry       Date:  2014-08-27       Impact factor: 4.785

Review 2.  Neuropsychiatric expression and catatonia in 22q11.2 deletion syndrome: An overview and case series.

Authors:  Nancy J Butcher; Erik Boot; Anthony E Lang; Danielle Andrade; Jacob Vorstman; Donna McDonald-McGinn; Anne S Bassett
Journal:  Am J Med Genet A       Date:  2018-05-19       Impact factor: 2.802

Review 3.  Prevalence of Catatonia and Its Moderators in Clinical Samples: Results from a Meta-analysis and Meta-regression Analysis.

Authors:  Marco Solmi; G Giorgio Pigato; Beatrice Roiter; Argentina Guaglianone; Luca Martini; Michele Fornaro; Francesco Monaco; Andrè F Carvalho; Brendon Stubbs; Nicola Veronese; Christoph U Correll
Journal:  Schizophr Bull       Date:  2018-08-20       Impact factor: 9.306

4.  Rapid Resolution of Prolonged Benzodiazepine-Refractory Catatonia With Electroconvulsive Therapy in an Adolescent Patient: A Case Report.

Authors:  James Luccarelli; Carlos Fernandez-Robles; Bryce Wininger; Jessica E Becker; Eric P Hazen; Michael E Henry
Journal:  J ECT       Date:  2022-04-05       Impact factor: 3.692

5.  Adverse Childhood Experiences Among Inpatient Youths with Severe and Early-Onset Psychiatric Disorders: Prevalence and Clinical Correlates.

Authors:  Xavier Benarous; Marie Raffin; Nicolas Bodeau; Dirk Dhossche; David Cohen; Angèle Consoli
Journal:  Child Psychiatry Hum Dev       Date:  2017-04

Review 6.  Autoantibody-associated psychiatric syndromes in children: link to adult psychiatry.

Authors:  Niels Hansen; Daniel Luedecke; Berend Malchow; Michael Lipp; Jonathan Vogelgsang; Charles Timäus; Tristan Zindler; Stefan Gingele; Simone Kühn; Jürgen Gallinat; Klaus Wiedemann; Johannes Denk; Nicole Moschny; Jens Fiehler; Thomas Skripuletz; Christian Riedel; Mike P Wattjes; Inga Zerr; Hermann Esselmann; Luise Poustka; Anne Karow; Hans Hartmann; Helge Frieling; Stefan Bleich; Jens Wiltfang; Alexandra Neyazi
Journal:  J Neural Transm (Vienna)       Date:  2021-05-31       Impact factor: 3.575

Review 7.  Psychiatric manifestations of treatable hereditary metabolic disorders in adults.

Authors:  Caroline Demily; Frédéric Sedel
Journal:  Ann Gen Psychiatry       Date:  2014-09-24       Impact factor: 3.455

8.  Attempted infanticide and suicide inaugurating catatonia associated with Hashimoto's encephalopathy: a case report.

Authors:  Laurence Lalanne; Marie-Emmanuelle Meriot; Elisabeth Ruppert; Marie-Agathe Zimmermann; Jean-Marie Danion; Pierre Vidailhet
Journal:  BMC Psychiatry       Date:  2016-01-19       Impact factor: 3.630

9.  Catatonia in Down syndrome: systematic approach to diagnosis, treatment and outcome assessment based on a case series of seven patients.

Authors:  Judith H Miles; Nicole Takahashi; Julie Muckerman; Kerri P Nowell; Muaid Ithman
Journal:  Neuropsychiatr Dis Treat       Date:  2019-09-20       Impact factor: 2.570

10.  Missense variants in ATP1A3 and FXYD gene family are associated with childhood-onset schizophrenia.

Authors:  Boris Chaumette; Vladimir Ferrafiat; Amirthagowri Ambalavanan; Alice Goldenberg; Alexandre Dionne-Laporte; Dan Spiegelman; Patrick A Dion; Priscille Gerardin; Claudine Laurent; David Cohen; Judith Rapoport; Guy A Rouleau
Journal:  Mol Psychiatry       Date:  2018-06-12       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.